Analysis of two US administrative databases indicates that glucocorticoid use is associated with a dose-dependent increase in postoperative infection risk in patients with rheumatoid arthritis undergoing elective total knee or hip replacement.
Findings from the SENSCIS trial indicate that the tyrosine kinase inhibitor nintedanib reduces the annual rate of decline in forced vital capacity among patients with systemic sclerosis-associated interstitial lung disease.
Patients initiating their first tumor necrosis factor inhibitor for psoriatic arthritis have a longer time to discontinuation and are less likely to switch treatment than those previously treated with a drug from the same class, say researchers.
Analysis of data from 21 randomized controlled trials indicates that the interleukin-17A inhibitor secukinumab has a favorable long-term safety profile among patients with psoriatic arthritis, ankylosing spondylitis, or psoriasis.
SMILE, an individualized and culturally tailored patient decision aid, has been shown to reduce decisional conflict regarding choice of immunosuppressive treatment in a randomized trial involving a diverse group of women with lupus nephritis.
Supervised low-load resistance training combined with partial blood flow restriction is as effective as high‐load resistance training in improving muscle strength and function in women with rheumatoid arthritis (RA), study findings indicate.
Approximately one in five people diagnosed with rheumatoid arthritis will need a knee or hip replacement during their remaining lifetime, shows an analysis of data from the UK’s National Health Service.
The ACR and the National Arthritis Foundation have published two guidelines on juvenile idiopathic arthritis, one providing recommendations for the treatment of polyarthritis, sacroiliitis, and enthesitis, and the other focusing on detecting and treating uveitis.
Findings from a systematic review and meta-analysis indicate that the incidence of herpes zoster among rheumatoid arthritis patients treated with Janus kinase inhibitors is higher than expected in this population, and baricitinib is associated with a significantly increased risk.
Clinic-based or inpatient rehabilitation programs are not superior to home-based programs for individuals who undergo total knee replacement without complications, suggests a systematic review and meta-analysis.
Namilumab induces a rapid and sustained clinically significant response in patients with moderate-to-severe rheumatoid arthritis, with a favorable tolerability profile, show results of the phase II NEXUS trial.
Patients initiating denosumab have a similar 3-year fracture risk to those initiating alendronate, regardless of sex, age, or fracture history, show results of a large study among Danish patients in routine clinical practice.
Increasing levels of high-density lipoprotein cholesterol are associated with a reduction in cardiovascular risk among rheumatoid arthritis patients undergoing treatment with the Janus kinase inhibitor tofacitinib, researchers report.
Findings from a systematic review suggest that long-term drug treatment is associated with a reduction in fracture risk among women with osteoporosis, with different agents having varying long-term safety profiles.